Skip to main content
Terug
Watch Compare

Apyx Medical Corp

Datakwaliteit: 100%
APYX
Nasdaq Manufacturing Measuring & Analyzing Instruments
€ 3,97
▲ € 0,16 (4,20%)
Marktkapitalisatie: 166,06 M
Prijs
€ 3,97
Marktkapitalisatie
166,06 M
Dagbereik
€ 3,82 — € 4,01
52-Weeksbereik
€ 0,83 — € 4,50
Volume
112.727
Openen € 3,83
50D / 200D Gem.
€ 3,73
6,31% above
50D / 200D Gem.
€ 3,07
29,27% above

Quick Summary

Belangrijkste Punten

Revenue grew 2,16% annually over 5 years — modest growth
Debt/Equity of 6,41 — high leverage
Negative free cash flow of -9,12 M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 7,70%
Capital efficient — spends only 2,11% of revenue on capex

Groei

Revenue Growth (5Y)
2,16%
Boven sectorgemiddelde (1,82%)
Revenue (1Y)9,86%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-171,15%
Onder sectorgemiddelde (-53,41%)
ROIC-10,83%
Net Margin-21,22%
Op. Margin-12,20%

Veiligheid

Debt / Equity
6,41
Boven sectorgemiddelde (0,31)
Current Ratio4,44
Interest Coverage-1,15

Waardering

PE (TTM)
-14,81
Onder sectorgemiddelde (-1,48)
P/B Ratio28,40
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E -14,8 -1,5
P/B 28,4 1,6
ROE % -171,2 -53,4
Net Margin % -21,2 -41,5
Rev Growth 5Y % 2,2 1,8
D/E 6,4 0,3

All Fundamental Metrics
Growth
Revenue Growth (1Y) 9,86% Revenue Growth (3Y) 0,47%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 2,16% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 52,84 M Net Income (TTM) -11,21 M
ROE -171,15% ROA -19,40%
Gross Margin 62,53% Operating Margin -12,20%
Net Margin -21,22% Free Cash Flow (TTM) -9,12 M
ROIC -10,83% FCF Growth (3Y) N/A
Safety
Debt / Equity 6,41 Current Ratio 4,44
Interest Coverage -1,15 Asset Turnover 0,91
Working Capital 37,81 M Tangible Book Value 5,85 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -14,81 Forward P/E N/A
P/B Ratio 28,40 P/S Ratio 3,14
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -5,49%
Market Cap 166,06 M Enterprise Value 178,43 M
Per Share
EPS (Diluted TTM) N/A Revenue / Share 1,26
FCF / Share -0,22 OCF / Share -0,19
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 2,11% FCF Conversion 81,30%
SBC-Adj. FCF -11,61 M Growth Momentum 7,70

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 52,84 M 48,10 M 52,35 M 44,51 M 48,52 M
Net Income -11,21 M -23,46 M -18,71 M -23,18 M -15,17 M
EPS (Diluted) — — -0,54 -0,67 -0,44
Gross Profit 33,04 M 29,36 M 33,76 M 29,13 M 33,60 M
Operating Income -6,45 M -18,85 M -17,26 M -23,56 M -14,45 M
EBITDA — — — — —
R&D Expenses 3,37 M 5,08 M 4,84 M 4,54 M 4,32 M
SG&A Expenses 15,80 M 18,86 M 22,20 M 20,48 M 18,62 M
D&A 655.000,0 599.000,0 692.000,0 890.000,0 903.000,0
Interest Expense 5,59 M 5,91 M 2,48 M 15.000,0 10.000,0
Income Tax 270.000,0 252.000,0 -2,43 M 367.000,0 380.000,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 66,84 M 64,84 M 79,24 M 51,78 M 68,72 M
Total Liabilities 52,01 M 50,51 M 52,32 M 13,98 M 14,71 M
Shareholders' Equity 14,54 M 14,21 M 26,70 M 37,58 M 53,70 M
Total Debt 37,50 M 37,50 M 33,19 M — —
Cash & Equivalents 31,74 M 31,74 M 43,65 M 10,19 M 30,87 M
Current Assets 58,47 M 56,44 M 70,36 M 42,97 M 60,74 M
Current Liabilities 11,70 M 10,72 M 12,74 M 11,85 M 13,21 M